107

You are in: General information > Relevant events

Relevant events

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the significant facts, as well as any other communications, are available in the Web page of the CNMV.

Year 2010
	02.09.2010 Grifols obtains FDA license in the US market for its IVIG Flebogamma® DIF 10% concentration (PDF 2 pág, 34KB)

	10.08.2010 Preliminary version of the F4 filed with the SEC in connection with the proposed acquisition of Talecris (Spanish Version - PDF 1 pages, 58KB)

	20.07.2010 Grifols obtains its first crédit rating from Standard & Poor's and Moody's ( PDF 3 pages, 68KB)

	23.06.2010 Final dividend 2009 (Spanish Version - PDF 2 pages, 140KB)

	21.06.2010 Information on the resolutions passed at the Annual General Shareholders Meeting on June 21st (Spanish Version - PDF 5 pages, 25KB)

	10.06.2010 Voting agreement -amendment (Spanish Version - PDF 207 pages, 1.83MB)

	10.06.2010 Agreement and Plan of Merger among Grifols and Talecris Biotherapeutics Holdings Corp PDF 173 pages, 517KB

	07.06.2010 Acquisition Announcement of Talecris Biotherapeutics Holdings Corp (Spanish Version - PDF 3 pages, 70KB)

	07.06.2010 Conference call announcement (Spanish Version - PDF 1 pages, 67KB)

	07.06.2010 Analyst and investors' presentation regarding acquisition of Talecris Biotherapeutics Holdings Corp (PDF - 27 pages, 865KB)

	07.06.2010 Voting agreement (PDF 128 pages, 944KB)

	18.05.2010 Notice of Annual General Meeting (PDF 4 pages, 20KB)

	13.01.2010 Resignation of Christian Purlow from the Board of Directors (Spanish Version - PDF 1 pages, 13KB)

Year 2009
	16.12.2009 Grifols and financial institutions unanimously agree the novation of the syndicated facility (PDF 2 pages, 57KB)

	15.12.2009 Interim Dividend 2009 – Clarification (PDF 1 pages, 50KB)

	14.12.2009 Interim Dividend 2009 (PDF 1 pages, 50KB)

	04.11.2009 Change of registered address (Spanish Version - PDF 1 pages, 41KB)

	07.10.2009 Grifols completes its USD600 million corporate bond issue in the US (PDF 2 pages, 45KB)

	29.09.2009 Grifols announces corporate debt issuance in USA (Spanish Version - PDF 1 pages, 18KB)

	28.05.2009 The shares of Grifols will be traded in the United States through ADRs (PDF 2 pages, 45KB)

	15.05.2009 Announcement on Grifols dividend payment (Spanish Version - PDF 2 pages, 118KB)

	15.05.2009 Information on the resolutions passed by the General Shareholders’ Meeting held on May 15th, 2009 (Spanish Version - PDF 5 pages, 101KB)

	08.04.2009 Annual General Meeting Announcement (Spanish Version - PDF 4 pages, 76KB)

	31.03.2009 Grifols signs two supply agreements in brazil (Spanish Version - PDF 1 page, 79KB)

	03.03.2009 Grifols acquires control over a Swiss and Australian group through a €25 million investment ( PDF 2 pages, 115KB)

Year 2008
	09.12.2008 Dr. Anna Veiga joins the Board of Directors of Grifols as independent director (Spanish Version - PDF 1 page - 10KB)

	14.10.2008 Flebogamma® DIF receives licensing in Australia (Spanish Version - PDF 2 pages - 33KB)

	13.06.2008 The Company submits agreements approved in the Annual General Meeting on June 13, 2008 (Spanish Version - PDF 5 pages - 70KB)

	13.06.2008 The Company announces a dividend payment for June 23, 2008 (Spanish Version - PDF 2 pages - 17KB)

	23.05.2008 Grifols obtains syndicated financing for 350 million euros (Spanish Version - PDF 2 pages - 68KB)

	23.05.2008 Annual General Meeting Announcement Complement (Spanish Version - PDF 1 page - 11KB)

	29.04.2008 Annual General Meeting Announcement (Spanish Version - PDF 14 pages - 234KB)

	29.04.2008 The Company notifies the resignation of Mr. Thomas E. Doster from his positions as member of the Board of Directors and the Appointments and Remunerations Committee (Spanish Version - PDF 1 page. - 11KB)

	12.03.2008 Grifols signs agreement with Stough Development Corporation to open 10 new plasma collection Centers in the United States (Spanish Version - PDF 2 pages. - 27KB)

	23.01.2008 Grifols closed without agreement the due diligence process started with the Italian company Diesse (Spanish Version - PDF 1 page. - 88KB)

Year 2007
	21.12.2007 Appointment of Edgar D. Jannotta as member of the Appointments and Remuneration Committee (Spanish Version - PDF 1 page - 12KB)

	29.10.2007 Grifols to announce Capital Investment Plan for €400 million over the next five years (PDF 2 pages - 107KB)

	27.08.2007 EMEA authorization to distribute Flebogammadif® in Europe (Spanish Version - PDF 1 page - 47KB)

	10.08.2007 Announcement of transfer of shares (Spanish Version - PDF 1 page - 18KB)

	20.06.2007 Announcement on Grifols dividend payment (Spanish Version - PDF 2 pages - 28KB)

	20.06.2007 Information on the resolutions passed by the General Shareholders’ Meeting held on June 20th, 2007 (Spanish Version - PDF 7 pages - 137KB)

	04.05.2007 Grifols enters into an agreement for the management of four new plasma centers in the USA (Spanish Version - PDF 1 page - 48KB)

	18.04.2007 Grifols has entered into an agreement for the acquisition of Diesse. The closing of the transaction is subject to the outcome of the due diligence review, which the company expects will last until next June. (Spanish Version - PDF 2 pages - 51KB)

	11.04.2007 Morgan Stanley & Co. International Ltd announces the completion of the placement (Spanish Version - PDF 1 page - 7KB)

	10.04.2007 Morgan Stanley & Co. International Ltd announces a private placement of 1.41% of Grifols S.A. share capital (accelerated bookbuilding) (Spanish Version - PDF 1 page - 11KB)

	01.02.2007 Extension of the Communication number 22.629 on the FDA approval for the indication of von Willebrand disease. (Spanish Version - PDF 2 pages - 30KB)

	01.02.2007 The FDA approves the indication of von Willebrand disease for Alphanate (Spanish Version - PDF 1 page - 68KB)

Year 2006
	27.12.2006 Grifols licensed by the FDA to market a new generation of IGIV in the United States (Spanish version - PDF 1 page - 25KB)

	20.12.2006 Appointment of new Director through co-option procedure (Spanish version - PDF 1 page - 17KB)

	21.11.2006 Amendment to the syndicated loan (Spanish version - PDF 1 page - 28KB)

	19.07.2006 Changes in the Board of Directors and other governing bodies of the Company (Spanish version - PDF 1 page - 18KB)

	19.06.2006 Additional information to the public subscription offer for shares of Grifols, S.A. (Spanish version - PDF 1 page - 61KB)

	22.05.2006 Information regarding the execution of the green shoe option over 7,000,000 shares of Grifols (Spanish version - PDF 1 page - 22KB)

	16.05.2006 Additional information to the information brochure of the public subscription offer for shares in GRIFOLS, S.A. (Spanish version - PDF 1 page - 30KB)

	15.05.2006 Additional information to the information brochure of the public subscription offer for shares in GRIFOLS, S.A. (Spanish version - PDF 2 pages - 34KB)

2005: GRIFOLS, S.A. sent no relevant fact during 2005 as it was not obliged to do so.